Form 4: Director Robert Ross Receives Xilio Therapeutics Options

Director Robert W. Ross was granted 5,000 stock options in Xilio Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Robert W. Ross acquired 5,000 stock options in Xilio Therapeutics, Inc. (XLO).
• The options were granted on June 11, 2026, with an exercise price of $7.99 per share.
• The options are set to expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance or outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of Xilio Therapeutics common stock.

Future Outlook

The options vest 100% on the earlier of June 11, 2027, or the date of the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to incentivize board members and align their interests with long-term corporate performance.

Comparison to Industry Standards

• The grant of 5,000 options is consistent with typical director compensation packages for small-cap biotechnology firms.
• Vesting schedules tied to annual meetings are a common governance practice to ensure director retention.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 11, 2027, or the next annual meeting.

Key Dates

Keywords

Xilio Therapeutics, XLO, Form 4, Insider Trading, Stock Options, Director Compensation